Physician profile
John Stephen Shymansky
NPI 1205832755
$17,391.79
in general payments reported to CMS, 2019-2025
31 companies · $15K in 2025
The $15K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $46.50 · 2021: $177 · 2022: $32.80 · 2023: $195 · 2024: $1,545 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $4,106 · Travel and Lodging: $1,052 · Education: $43.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,795.00 |
| Food and Beverage | $4,105.86 |
| Travel and Lodging | $1,051.99 |
| Education | $43.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $14,191.73 | 2023-2025 | |
| Abbvie INC. | $660.29 | 2021-2025 | |
| Eisai INC. | $590.13 | 2024-2025 | |
| Biogen, INC. | $275.82 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Pfizer INC. | $203.61 | 2024-2025 | |
| Genentech USA, INC. | $163.48 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Lundbeck LLC | $135.48 | 2024-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $113.74 | 2024-2025 | Kisunla, Amyvid, Emgality |
| Acadia Pharmaceuticals INC | $109.34 | 2025 | Nuplazid, Daybue |
| Amgen INC. | $102.72 | 2019-2025 | Uplizna |
| Emd Serono, INC. | $92.47 | 2019-2025 | |
| Celgene Corporation | $86.68 | 2024-2025 | Zeposia |
| Vanda Pharmaceuticals INC. | $78.23 | 2025 | Ponvory |
| Argenx US, INC. | $75.64 | 2025 | Vyvgart Hytrulo |
| Avadel Cns Pharmaceuticals, LLC | $75.21 | 2024-2025 | Lumryz |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $55.81 | 2024-2025 | Rystiggo |
| Genentech, INC. | $49.95 | 2021 | |
| Alexion Pharmaceuticals, INC. | $47.05 | 2024-2025 | Ultomiris |
| Supernus Pharmaceuticals, INC. | $32.34 | 2019 | |
| Livanova USA, INC. | $29.61 | 2025 | Vns Therapy |
| Novartis Pharmaceuticals Corporation | $27.60 | 2025 | |
| Janssen Biotech, INC. | $25.73 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $24.90 | 2025 | Austedo Xr |
| Neurelis, INC. | $24.24 | 2024 | Valtoco |
| Takeda Pharmaceuticals U.S.A., INC. | $23.61 | 2025 | Hyqvia |
| Genzyme Corporation | $23.05 | 2025 | |
| Mallinckrodt Hospital Products INC. | $21.32 | 2025 | Acthar |
| Grifols USA, LLC | $19.86 | 2024 | Gamunex-C |
| Azurity Pharmaceuticals, INC. | $19.04 | 2025 | Horizant |
| Horizon Therapeutics Plc | $13.11 | 2023 | Uplizna |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Shymansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.